{"entry":[{"fullUrl":"http://localhost:3000/R4/ResearchStudy/2022-500014-26-00","resource":{"phase":{"coding":[{"code":"phase-3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","display":"Phase 3","version":"4.0.1"}],"text":"Research Study Phase"},"identifier":[{"use":"official","assigner":{"display":"Reference to primary assigner","type":"Organization"},"value":"INDISPONIBLE"},{"use":"secondary","assigner":{"reference":"Organization/ctis","display":"Reference to secondary assigner","type":"Organization"},"value":"2022-500014-26-00"}],"sponsor":{"reference":"Organization/2022-500014-26-00-primary-sponsor","display":"Reference to primary sponsor","type":"Organization"},"extension":[{"valueReference":{"reference":"Organization/2022-500014-26-00-secondary-sponsor","display":"Reference to secondary sponsor","type":"Organization"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-secondary-sponsor"},{"valueString":"Diseases [C] - Neoplasms [C04]","url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area"},{"extension":[{"valueString":"INDISPONIBLE","url":"labelValue"},{"valueCodeableConcept":{"coding":[{"code":"human-use","system":"http://hl7.org/fhir/title-type","display":"Human use","version":"5.0.0"}],"text":"Label Type"},"url":"labelType"}],"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"},{"extension":[{"valueString":"INDISPONIBLE","url":"labelValue"},{"valueCodeableConcept":{"coding":[{"code":"acronym","system":"http://hl7.org/fhir/title-type","display":"Acronym","version":"5.0.0"}],"text":"Label Type"},"url":"labelType"}],"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-label"},{"valuePeriod":{"start":"2022-06-30T00:00:00.000Z"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period"}],"description":"INDISPONIBLE","title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","enrollment":[{"reference":"#2022-500014-26-00-enrollment-group-id","display":"Reference to group detailing study characteristics","type":"Group"}],"condition":[{"coding":[{"display":"Locally-Advanced or Metastatic breast cancer (MBC)"}],"text":"Disease Condition"},{"coding":[{"code":"10070575","system":"http://terminology.hl7.org/CodeSystem/mdr","display":"MedDRA","version":"2.0.1"},{"code":"10065430","system":"http://terminology.hl7.org/CodeSystem/mdr","display":"MedDRA","version":"2.0.1"}],"text":"MedDRA Condition"}],"contained":[{"actual":true,"quantity":21,"id":"2022-500014-26-00-enrollment-group-id","type":"person","characteristic":[{"valueCodeableConcept":{"coding":[{"code":"male","system":"http://hl7.org/fhir/administrative-gender","display":"Male","version":"5.0.0"},{"code":"female","system":"http://hl7.org/fhir/administrative-gender","display":"Female","version":"5.0.0"}],"text":"Genders"},"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"valueRange":{"low":{"comparator":">=","unit":"years","value":65}},"exclude":false},{"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"valueRange":{"high":{"comparator":"<=","unit":"years","value":64},"low":{"comparator":">=","unit":"years","value":18}},"exclude":false},{"valueCodeableConcept":{"coding":[{"display":"Donn√©es non disponible"}],"text":"Research Study Group Category"},"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false},{"valueCodeableConcept":{"coding":[{"display":"Women of child bearing potential not using contraception, Women of child bearing potential using contraception"}],"text":"Study Population"},"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false},{"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Inclusion Criteria"},"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":false},{"valueCodeableConcept":{"coding":[{"display":"INDISPONIBLE"}],"text":"Study Exclusion Criteria"},"code":{"coding":[{"display":"INDISPONIBLE"}],"text":"Group characteristic code"},"exclude":true}],"resourceType":"Group"}],"site":[{"reference":"Location/0-ctis-site","display":"Reference to site","type":"Location"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"contact":[{"name":"Head of EU Trial Information Support Line-TISL, Switzerland","telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]},{"extension":[{"valueCodeableConcept":{"coding":[{"code":"SCI","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","display":"Scientifique / Scientific","version":"0.1.0"}],"text":"Contact Type"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type"}],"name":"INDISPONIBLE INDISPONIBLE","telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]},{"extension":[{"valueCodeableConcept":{"coding":[{"code":"PUB","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","display":"Publique / Public","version":"0.1.0"}],"text":"Contact Type"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type"}],"name":"INDISPONIBLE INDISPONIBLE","telecom":[{"system":"phone","use":"work","value":"INDISPONIBLE"},{"system":"email","use":"work","value":"INDISPONIBLE"}]}],"location":[{"coding":[{"code":"BE","system":"urn:iso:std:iso:3166","display":"Belgium","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"DE","system":"urn:iso:std:iso:3166","display":"Germany","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"ES","system":"urn:iso:std:iso:3166","display":"Spain","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"FR","system":"urn:iso:std:iso:3166","display":"France","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"HU","system":"urn:iso:std:iso:3166","display":"Hungary","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"IT","system":"urn:iso:std:iso:3166","display":"Italy","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"PL","system":"urn:iso:std:iso:3166","display":"Poland","version":"4.0.1"}],"text":"Countries of recruitment"},{"coding":[{"code":"PT","system":"urn:iso:std:iso:3166","display":"Portugal","version":"4.0.1"}],"text":"Countries of recruitment"}],"id":"2022-500014-26-00","category":[{"coding":[{"display":"REG536"}],"text":"Regulation Code"}],"resourceType":"ResearchStudy","status":"active"}}],"link":[{"relation":"self","url":"http://localhost:3000/R4/ResearchStudy?_getpagesoffset=0"},{"relation":"next","url":"http://localhost:3000/R4/ResearchStudy?_getpagesoffset=2"}],"resourceType":"Bundle","total":1,"type":"searchset"}